Access to an optimal treatment. Current situation

Access to an optimal treatment is determined by several factors, like availability, pricing/funding, and acceptability. In Latin America (LA), one of the regions with more disparities particularly on healthcare in the world, access is affected by other factors, including socio-demographic factors li...

Full description

Saved in:
Bibliographic Details
Published in:Clinical rheumatology 2015-03, Vol.34 (Suppl 1), p.59-66
Main Authors: Ugarte-Gil, Manuel F., Silvestre, Adriana M. R., Pons-Estel, Bernardo A.
Format: Article
Language:English
Subjects:
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - economics
Costs and Cost Analysis
Health Services Accessibility - economics
Humans
Latin America
Medicine
Medicine & Public Health
Poverty
Primary Health Care - standards
Review
Review Article
Rheumatology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Access to an optimal treatment is determined by several factors, like availability, pricing/funding, and acceptability. In Latin America (LA), one of the regions with more disparities particularly on healthcare in the world, access is affected by other factors, including socio-demographic factors like poverty, living in rural regions, and/or health coverage. Regarding rheumatoid arthritis (RA), an inadequate access to specialists leads to diagnosis and treatment delays diminishing the probability of remission or control. Unfortunately, in almost every LA country, there are cities with more than 100,000 inhabitants without rheumatologists; furthermore, a primary care reference system is present in only about half the countries. In the public health system, coverage of biologic disease-modifying antirheumatic drugs occurs for less than 10 % of the patients in about half of the countries. Also, as healthcare providers based their funding decisions mainly in direct costs instead of on patient-centered healthcare quality indicators, access to new drugs is more complicated in this region than in high-income countries. More accurate epidemiological data from LA need to be obtained in order to improve the management of patients with rheumatic diseases in general and RA in particular.
ISSN:0770-3198
1434-9949
DOI:10.1007/s10067-015-3018-7